Draft

165  Icslaba Prn And Maintenance

165.1 Summary

  • Update on ICS LABA for prn and long acting
  • An update in case anyone missed it: albuterol in asthma is optional.
  • Big updates in 2020 asthma guidelines - In case you missed it
  • PRN albuterol for Asthma is on the way out.
  • GINA 2020 and, to a less extent, NHLBI 2020 Update (released yesterday) both moving to ICS-LABA as PREFERRED reliever med, over albuterol.
  • Why?
  • -SABA use masks insufficient ICS. Increasing ICS can avert exacerbations, SABAs can’t.
  • -poor adherence to ICS with intermittent symptoms when separate
  • -safety concerns from SABA overuse
  • https://erj.ersjournals.com/content/53/4/1802223

165.2 Slide outline

165.2.1 Slide 1

  • Update on ICS LABA for prn and long acting ### Slide 2
  • An update in case anyone missed it: albuterol in asthma is optional.
  • Big updates in 2020 asthma guidelines - In case you missed it
  • PRN albuterol for Asthma is on the way out.
  • GINA 2020 and, to a less extent, NHLBI 2020 Update (released yesterday) both moving to ICS-LABA as PREFERRED reliever med, over albuterol.
  • Why?
  • -SABA use masks insufficient ICS. Increasing ICS can avert exacerbations, SABAs can’t.
  • -poor adherence to ICS with intermittent symptoms when separate
  • -safety concerns from SABA overuse
  • https://erj.ersjournals.com/content/53/4/1802223

165.3 Learning objectives

  • Update on ICS LABA for prn and long acting
  • An update in case anyone missed it: albuterol in asthma is optional.
  • Big updates in 2020 asthma guidelines - In case you missed it
  • PRN albuterol for Asthma is on the way out.
  • GINA 2020 and, to a less extent, NHLBI 2020 Update (released yesterday) both moving to ICS-LABA as PREFERRED reliever med, over albuterol.

165.4 Bottom line / summary

  • Update on ICS LABA for prn and long acting
  • An update in case anyone missed it: albuterol in asthma is optional.
  • Big updates in 2020 asthma guidelines - In case you missed it
  • PRN albuterol for Asthma is on the way out.
  • GINA 2020 and, to a less extent, NHLBI 2020 Update (released yesterday) both moving to ICS-LABA as PREFERRED reliever med, over albuterol.

165.5 Approach

  1. TODO: Outline the initial assessment or decision point.
  2. TODO: Outline the next diagnostic or management step.
  3. TODO: Outline follow-up or escalation criteria.

165.6 Red flags / when to escalate

  • TODO: List red flags that require urgent escalation.

165.7 Common pitfalls

  • TODO: Capture common errors or missed steps.

165.8 References

TODO: Add landmark references or guideline citations.

165.9 Slides and assets

165.10 Source materials